Incyte Strikes CMS Deal for Jakafi Pricing, Secures Exemption from Future Mandates
INCY sits 52% above its 52-week low of $81.09.
Summary
Incyte reached a new agreement with CMS to improve access to Jakafi and Jakafi XR, with state Medicaid programs gaining access at prices aligned with advanced nations. The company expects an exemption from future CMS pricing mandates, including GUARD and GLOBE, and does not expect the agreement to affect 2026 financial guidance. This follows a prior CMS settlement in June related to Opzelura, but this deal covers different products and adds a forward-looking exemption. The agreement removes a regulatory overhang and secures favorable pricing terms for key products.
At the time of this announcement, INCY was trading at $123.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $25B. The 52-week trading range was $81.09 to $132.60. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.